Gamco Investors INC. ET AL purchased a new position in shares of TESARO Inc (NASDAQ:TSRO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 97,450 shares of the biopharmaceutical company’s stock, valued at approximately $7,236,000. Gamco Investors INC. ET AL owned approximately 0.18% of TESARO at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. BlackRock Inc. grew its position in TESARO by 1.5% during the third quarter. BlackRock Inc. now owns 4,285,890 shares of the biopharmaceutical company’s stock worth $167,194,000 after buying an additional 64,579 shares in the last quarter. Vanguard Group Inc boosted its holdings in shares of TESARO by 3.6% in the 3rd quarter. Vanguard Group Inc now owns 3,336,421 shares of the biopharmaceutical company’s stock valued at $130,154,000 after purchasing an additional 116,337 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of TESARO by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,336,421 shares of the biopharmaceutical company’s stock valued at $130,154,000 after purchasing an additional 116,337 shares in the last quarter. Frontier Capital Management Co. LLC boosted its holdings in shares of TESARO by 77.9% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 3,139,778 shares of the biopharmaceutical company’s stock valued at $122,483,000 after purchasing an additional 1,375,361 shares in the last quarter. Finally, BB Biotech AG boosted its holdings in shares of TESARO by 20.8% in the 3rd quarter. BB Biotech AG now owns 2,931,802 shares of the biopharmaceutical company’s stock valued at $114,370,000 after purchasing an additional 505,000 shares in the last quarter.

NASDAQ TSRO opened at $74.96 on Tuesday. TESARO Inc has a twelve month low of $23.41 and a twelve month high of $75.16. The firm has a market cap of $4.13 billion, a P/E ratio of -8.17 and a beta of 0.38.

TSRO has been the topic of a number of research analyst reports. BidaskClub raised TESARO from a “buy” rating to a “strong-buy” rating in a report on Friday, October 19th. Oppenheimer set a $83.00 target price on TESARO and gave the company a “buy” rating in a report on Sunday, November 11th. Wells Fargo & Co downgraded TESARO from an “outperform” rating to a “market perform” rating in a report on Monday, December 3rd. Bank of America raised their target price on TESARO from $38.00 to $39.00 and gave the company a “neutral” rating in a report on Friday, November 2nd. Finally, Cowen reaffirmed a “hold” rating and issued a $38.00 target price on shares of TESARO in a report on Monday, October 22nd. Eighteen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $79.05.

COPYRIGHT VIOLATION NOTICE: “Gamco Investors INC. ET AL Purchases New Stake in TESARO Inc (TSRO)” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2019/02/05/gamco-investors-inc-et-al-purchases-new-stake-in-tesaro-inc-tsro.html.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Story: The benefits and drawbacks of dollar cost averaging

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.